Q2

El Paso’s Desert Imaging Acquired by Private Equity-Backed Radiology Company

Dallas-based private equity firm Panos Partners announces its healthcare radiology platform company is acquiring Desert Imaging. Diagnostic Imaging Centers of Texas, or “DICOT,” is adding the El Paso, Texas, radiology group for an undisclosed sum. Founded in 2002, Desert Imaging employs four physicians and operates five outpatient centers across the western border city. DICOT now

El Paso’s Desert Imaging Acquired by Private Equity-Backed Radiology Company Read More »

Behavioral Health Nonprofits Best Point, Butler Merge with Combined $65M Annual Revenue

Ohio behavioral health nonprofits Butler Behavioral Health and Best Point Education and Behavioral Health have merged. Following the deal, Butler will be a wholly owned subsidiary of Cincinnati-based Best Point Education and Behavioral Health. The merger came to fruition after Best Point evaluated five other potential partnerships over the last 18 months, but ultimately found

Behavioral Health Nonprofits Best Point, Butler Merge with Combined $65M Annual Revenue Read More »

Premier, Inc. Expands Clinical Decision Support (CDS) Capabilities with Acquisition of IllumiCare

Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare performance improvement company, announces the acquisition of IllumiCare, a healthcare technology firm known for its EMR-agnostic platform. The platform marries clinical and financial data at the point of care to help providers make the best possible clinical decisions at the best possible cost. The acquisition significantly expands

Premier, Inc. Expands Clinical Decision Support (CDS) Capabilities with Acquisition of IllumiCare Read More »

TuHURA Biosciences Completes Acquisition of Kineta

TuHURA Biosciences, Inc. (NASDAQ:HURA) (“TuHURA”), a Phase 3 immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, announces the successful completion of the acquisition of Kineta, Inc. (OTCPK:KANT) (“Kineta”), the maker of the novel VISTA inhibiting mAb formerly known as KVA1213, now renamed as TBS-2025. “While TuHURA’s IFx-2.0 is being investigated for its

TuHURA Biosciences Completes Acquisition of Kineta Read More »

Scroll to Top